

Tomas Cihlar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10083293/publications.pdf>

Version: 2024-02-01

24
papers

9,258
citations

361413

20
h-index

642732

23
g-index

25
all docs

25
docs citations

25
times ranked

12209
citing authors

#	ARTICLE	IF	CITATIONS
1	Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19. <i>Antiviral Therapy</i> , 2022, 27, 135965352210827.	1.0	10
2	PREVAIL IV: A Randomized, Double-Blind, 2-Phase, Phase 2 Trial of Remdesivir vs Placebo for Reduction of Ebola Virus RNA in the Semen of Male Survivors. <i>Clinical Infectious Diseases</i> , 2021, 73, 1849-1856.	5.8	24
3	Prodrugs of a 2'-CN-4-Aza-7,9-dideazaadenosine Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSV. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 5001-5017.	6.4	40
4	Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice. <i>Cell Reports</i> , 2021, 36, 109450.	6.4	38
5	Remdesivir is efficacious in rhesus monkeys exposed to aerosolized Ebola virus. <i>Scientific Reports</i> , 2021, 11, 19458.	3.3	9
6	Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. <i>Nature Communications</i> , 2020, 11, 222.	12.8	1,376
7	A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. <i>Nature Communications</i> , 2020, 11, 5214.	12.8	179
8	Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. <i>Nature</i> , 2020, 585, 273-276.	27.8	592
9	Remdesivir (GS-5734) Is Efficacious in Cynomolgus Macaques Infected With Marburg Virus. <i>Journal of Infectious Diseases</i> , 2020, 222, 1894-1901.	4.0	41
10	Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 6771-6776.	7.1	735
11	Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. <i>Cell Reports</i> , 2020, 32, 107940.	6.4	412
12	Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. <i>Antiviral Research</i> , 2019, 169, 104541.	4.1	398
13	Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	166
14	Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. <i>MBio</i> , 2018, 9, .	4.1	1,142
15	Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1- <i>f</i>][triazin-4-amino] Adenine Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1648-1661.	6.4	547
16	GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. <i>Scientific Reports</i> , 2017, 7, 43395.	3.3	373
17	Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	1,279
18	TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	47

#	ARTICLE	IF	CITATIONS
19	Accelerating Drug Development: Antiviral Therapies for Emerging Viruses as a Model. Annual Review of Pharmacology and Toxicology, 2017, 57, 155-169.	9.4	23
20	Current status and prospects of HIV treatment. Current Opinion in Virology, 2016, 18, 50-56.	5.4	249
21	Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature, 2016, 531, 381-385.	27.8	1,245
22	Discovery of GS-8374, a potent human immunodeficiency virus type 1 protease inhibitor with a superior resistance profile. MedChemComm, 2011, 2, 1093.	3.4	13
23	Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Research, 2010, 85, 39-58.	4.1	314
24	Tenofovir and Adefovir as Antiviral Agents. , 0, , 601-630.		4